Zydus Receives USFDA EIR for Baddi Facility
Zydus Lifesciences has announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drugs Administration (USFDA) for its manufacturing facility in Baddi.
The inspection was conducted from August 4th to 13th, 2025, and resulted in four observations. The EIR has classified the facility as Voluntary Action Indicated (VAI), and the USFDA has concluded the inspection as closed.
Zydus Lifesciences Ltd. is a global lifesciences company that discovers, develops, manufactures, and markets a range of healthcare therapies.
The USFDA has concluded this inspection as closed.
Author's summary: Zydus receives USFDA report.
More News
- US and Lebanese navies complete ‘Resolute Union 26’ maritime exercise
- Toronto Blue Jays' Davis Schneider hilariously roasts dad after massive World Series home run | Sports
- Why Baptism Must Precede Membership and the Table | SHARPER IRON
- How Artissima’s Curatorial and Institutional DNA Sets It Apart from the Mega-Fairs
- Stranger Things 5 Trailer Unleashes All-Out War in Hawkins Ahead of Final Season! | SPIN1038
- NBA approves $10 billion Lakers sale to Mark Walter
- Over £8,000 raised to support family of North Belfast man who tragically drowned on holiday in Turkey
- Nordic-Baltic regional unity is our biggest advantage - Vucans
- Troy man pleads guilty in hit-and-run crash that killed 93-year-old man in Cohoes
- How Discrimination and Stress Impact the Mental Health of Young Sexual Minority Men